Pfizer is undervalued as markets fixate on its patent cliff, overlooking strong cash flows, pipeline upside, and a 7% yield.

Pfizer expanded its cost-cutting ... program resulting from the Inflation Reduction Act will hurt sales by $1 billion, dampening growth by approximately 1.6% compared with 2024. Stripping out ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

The company said it is on track to deliver overall net cost savings of roughly $4.5 billion by the end of 2025 from its cost-cutting program. Pfizer believes ... Stripping out one-time items ...

Photo: ABC News Pfizer on Tuesday reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker looks to turn around its business postpandemic.

No large pharma company has traversed this decade's ups and downs quite like Pfizer. As the company rolls ahead with ... May revealed a plan to cut additional costs out to 2027.